Acumen Pharmaceuticals (NASDAQ:ABOS) Coverage Initiated at Deutsche Bank Aktiengesellschaft
Deutsche Bank Aktiengesellschaft initiated coverage on shares of Acumen Pharmaceuticals (NASDAQ:ABOS – Free Report) in a research report released on Tuesday, MarketBeat Ratings reports. The firm issued a buy rating and a $8.00 price target on the stock. Acumen Pharmaceuticals Trading Up 3.1 % Acumen Pharmaceuticals stock opened at $3.00 on Tuesday. Acumen Pharmaceuticals has […]
More Stories
Universal Technical Institute (NYSE:UTI) Earns Buy Rating from Rosenblatt Securities
Rosenblatt Securities reiterated their buy rating on shares of Universal Technical Institute (NYSE:UTI – Free Report) in a research report...
StockNews.com Lowers Trex (NYSE:TREX) to Sell
StockNews.com downgraded shares of Trex (NYSE:TREX – Free Report) from a hold rating to a sell rating in a research...
Stryker (NYSE:SYK) Given Overweight Rating at Piper Sandler
Piper Sandler restated their overweight rating on shares of Stryker (NYSE:SYK – Free Report) in a research note issued to...
StockNews.com Lowers Esperion Therapeutics (NASDAQ:ESPR) to Hold
StockNews.com lowered shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) from a buy rating to a hold rating in a...
Nuvation Bio (NYSE:NUVB) Receives Outperform Rating from Wedbush
Wedbush reaffirmed their outperform rating on shares of Nuvation Bio (NYSE:NUVB – Free Report) in a research report sent to...
International Flavors & Fragrances (NYSE:IFF) Price Target Raised to $117.00
International Flavors & Fragrances (NYSE:IFF – Free Report) had its price objective raised by Oppenheimer from $116.00 to $117.00 in...